Isoalantolactone mediates the degradation of BCR-ABL protein in imatinib-resistant CML cells by down-regulating survivin

• Published in: Cell cycle (Georgetown, Tex.) Vol. 22; no. 12; pp. 1407 - 1420
• Main Authors: Yin, Shan-Shan, Chen, Chen, Liu, Zhen, Liu, Shan-Ling, Guo, Jia-Hui, Zhang, Chao, Zhang, Quan-Wu, Gao, Feng-Hou
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 18.06.2023
• Subjects: Apoptosis; BCR-ABL; Caspase 3; Cell Line, Tumor; Cell Proliferation; chronic myeloid leukemia; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate - pharmacology; Imatinib Mesylate - therapeutic use; Isoalantolactone; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism; protein degradation; Research Paper; RNA, Messenger; Survivin; Ubiquitins - pharmacology; Ubiquitins - therapeutic use; survivin; chronic myeloid leukemia; Isoalantolactone; protein degradation; BCR-ABL; caspase-3
• ISSN: 1538-4101; 1551-4005
• DOI: 10.1080/15384101.2023.2209963

Isoalantolactone (Iso) is a bioactive lactone isolated from the root of Inula helenium L, which has been reported to have many pharmacological effects. To investigate the role and mechanism of isoalantolactone in chronic myeloid leukemia (CML), we first investigated isoalantolactone's anti-proliferative effects on imatinib-sensitive and imatinib-resistant CML cells by CCK8. Flow cytometry was used to detect isoalantolactone-induced cell apoptosis. Survivin was overexpressed in KBM5 and KBM5 T315I cells using the lentivirus vector pSIN-3×flag-PURO. In KBM5 and KBM5 T315I cells, shRNA was used to knockdown survivin. Cellular Thermal Shift Assay (CETSA) was used to detect the interaction between isoalantolactone and survivin. The ubiquitin of survivin induced by isoalantolactone was detected through immunoprecipitation. Quantitative polymerase-chain reaction (Q-PCR) and western blotting were used to detect the levels of mRNA and protein. Isoalantolactone inhibits the proliferation and promotes apoptosis of imatinib-resistant CML cells. Although isoalantolactone inhibits the proteins of BCR-ABL and survivin, it cannot inhibit survivin and BCR-ABL mRNA levels. Simultaneously, it was shown that isoalantolactone can degrade survivin protein by increasing ubiquitination. It was demonstrated that isoalantolactone-induced survivin mediated downregulation of BCR-ABL protein. It was also revealed that isoalantolactone triggered BCR-ABL protein degradation via caspase-3. Altogether, isoalantolactone inhibits survivin through the ubiquitin proteasome pathway, and mediates BCR-ABL downregulation in a caspase-3 dependent manner. These data suggest that isoalantolactone is a natural compound, which can be used as a potential drug to treat TKI-resistant CML.